Opinion

Over the last decade, groundbreaking chimeric antigen receptor (CAR) T-cell immunotherapies have become a well-established cancer treatment modality. Clinical research continues to demonstrate the encouraging potential this approach holds for treating a wide array of conditions while increasing safety, tolerability, and efficiency in manufacturing. Atara Biotherapeutics, a California-based biotechnology company, seeks to harness the immune […]

As part of the Fall Issue of DDW’s Market Report, Dr Henry Li, CSO, Crown Bioscience examines cycles of innovation in the Chinese life sciences industry and how they provide opportunities for global drug discovery breakthroughs.  Drug research and development in China has changed dramatically since the turn of the century and will continue to evolve […]

In the second part of this series helping researchers determine whether a LIMs or an ELN is right for them, Barry Bunin, CEO Collaborative Drug Discovery, continues his guide to understanding what a LIMS is and how it differs from other scientific data management systems. Read Part 1 here. Pharmaceutical labs often run a variety of high-throughput workflows […]

Marjie Hadad talks to cell therapy expert and Kadimastem CEO Asaf Shiloni about the potential of cell therapy.  “I am attracted to cell therapy because traditional medicine has reached its limitation in treating the ailments of the 21st century,” says Asaf Shiloni, 20-year biotechnology executive, cell therapy expert and CEO of Kadimastem.  He continues: “It’s known today that most diseases develop because of […]

Combination immunotherapies are one of the most exciting advanced therapy medicinal products (ATMP) being developed, with incredible potential for treating cancer, says Panagiotis Parsonidis, a molecular biologist and lead researcher at RGCC. DDW speaks to him about VAXO-Q-RE developments, a combination immunotherapy that will soon enter clinical trials.  VAXO-Q-RE is an advanced combination immunotherapy that consists of […]

Rebecca W. Doerge, Glen de Vries Dean of the Mellon College of Science and Professor of Biological Sciences and Statistics and Data Science at Carnegie Mellon University was issued a challenge by the administration to elevate the reputation of the school to rival that of their IT and engineering colleges. Her answer was to invest […]

Hemispherian is a Norwegian pharmaceutical company focused on developing a novel class of small molecule drugs (GLIX) that target the TET2 enzyme. Lu Rahman spoke to Zeno Albisser, CEO, to find out more about the company’s expertise.  LR: What it does Hemispherian do?  ZA: We are focused on developing a novel class of small molecule drugs (GLIX) that target the TET2 enzyme. […]

RareCan is a new company based in the UK. Its aim is to accelerate research into rare cancers. However, finding suitable patients willing to take part in research and trials of new drugs is difficult, which impacts the discovery process. Professor Andy Hall, Founding Director and Chief Scientific Officer at RareCan talks to DDW’s Megan Thomas.  MT: Could you explain […]

Machine learning (ML) holds the promise to revolutionise drug discovery. By integrating vast datasets into predictive models, ML will help researchers arrive at the optimal candidate compounds more quickly, disrupting the long cycle times of preclinical discovery research. DEL technology is unmatched in its ability to produce ultra-large datasets. By harnessing the power of next-generation […]